CVRx, Inc. (CVRX) Earnings Call Transcript & Summary

November 5, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 36 min

Earnings Call Speaker Segments

Mark Klausner

executive
#1

Good afternoon, and thanks for being with us for CVRx's third quarter 2026 earnings conference call. On the call with me today are Kevin Hykes, the company's President and Chief Executive Officer, and Jared Oasheim, our Chief Financial Officer, who will go over our financial results. We're also glad to have John Landry here, the company's Incoming Chief Financial Officer, who came on board in October and will take on the CFO role after our Form 10-Q is filed. Today's remarks will include forward-looking statements, among them statements regarding financial guidance. Such statements rest on plans and expectations as of today, and those may change over time. Beyond that, actual results might differ materially because of various risks and uncertainties, including the ones set out in the earnings release issued before this call and in the company's SEC filings. At this point, I'd like to hand the call over to CVRx's President and Chief Executive Officer, Kevin Hykes.

Kevin Hykes

executive
#2

Thanks, Mark. Good afternoon, and thank you for joining our third quarter 2026 earnings call. In the third quarter we delivered total revenue of $13.8 million, which came in within our guidance range, and gross margin held steady at 87%. Revenue was down 6.1% compared with the same quarter last year; U.S. revenue fell 4% and Europe was down 27%. We kept working to stabilize our U.S. sales organization, and a second major payer added a Barostim coverage policy for its Medicare Advantage enrollees. That said, the headwinds we've been working through have had a bigger impact and have lasted longer than we anticipated, and while tenure is improving, the effect on performance is taking longer to show up than we had expected, partly because of these headwinds. I'd like to provide a more complete view of the forces affecting our business. Three topics will be covered: the three headwinds we face—reimbursement, physician champion turnover, and field execution—along with our response to each; the approaches succeeding in our most stable regions and how we're broadening them; and the clinical evidence accumulating for Barostim. After that, I'll introduce John Landry, our incoming Chief Financial Officer, and then Jared will go through our financial results. Reimbursement is the first headwind—more precisely, the shift in behavior by our largest Medicare Advantage payer, which worsened further as the third quarter progressed. When it comes to reimbursement visibility, we only see the prior authorizations in which we're involved, and that's probably under half of the total. For the ones we handle ourselves, approvals that used to come through in days now stretch to three months or more. With this particular payer, the 30-day approval rate has dropped to roughly 12%, down from a peak of 83% in 2025, and the 90-day rate remains under 35%, which tells us a lot of prior authorizations are still going through appeals, with our team exploring every avenue, including in the end an administrative law judge hearing, which can tack 100 or more days onto the approval process. When our customers handle prior authorizations themselves for this particular payer, more than 80% of those are probably dropped after the first denial. Because payer behavior has shifted so dramatically, we think certain physicians have stopped recommending Barostim therapy for patients covered by this payer, which put additional pressure on our growth during the quarter. An increase in approved prior authorizations for patients covered by Humana partly offset this decline, yet our overall Medicare Advantage approval rate at 30 days fell to 51% by the end of Q3, down from 60% in Q2. Over the longer term, we remain confident that we can work through this temporary reimbursement challenge. Sadly, this problem isn't limited to just one insurer. Doubts about how new treatments get reimbursed have made certain customers warier about launching and expanding new initiatives. Such customers are setting up review points so that payment stays consistent across their mix of payers before they agree to place more implants. Frequently a customer requires time to assemble a group of patients whose insurance circumstances represent standard coverage, begin treating those patients, and then pause to confirm or challenge payment with each payer. One large health system has had over twelve patients with approved prior authorizations sitting for multiple quarters, waiting on the hospital to complete that payment verification step. We're tackling these reimbursement hurdles through several approaches so Barostim adoption can move faster. First, for the prior authorizations we manage on behalf of accounts, we continue appealing denials at every level, and we'll take the fight for approval to an administrative law judge when needed. What we've seen with Humana is that winning before administrative law judges ultimately produces a written coverage policy. In addition, over the last few months we have brought on field-based reimbursement managers whose job is to work side by side with accounts to cut down on billing and coding mistakes, make sure claims are paid correctly and on time, and help local teams sort out problems whenever payment issues come up. We are also using those same field-based people to support and lessen the burden of the longer payment trial periods we are seeing in the market. While doing that, we keep strengthening the coverage base for Barostim therapy. Once we moved to a Category I code in January, we secured our first two written Medicare Advantage coverage policies—Humana issued one in Q2, and a second major payer followed in July. Combined, those policies account for 21% of Medicare Advantage lives. Appeals and ALJ rulings are gaining momentum with most payers, and every new written coverage policy strengthens our position with payers that haven't issued one yet. Payment rates have improved too: effective October 1, the national average inpatient rate rose from $43,000 to $45,000. On the outpatient side, the latest traditional Medicare claims data indicates that 100% of claims submitted in Q1 of 2026 were paid, which is the first time we have reached that level of payment consistency. The second challenge is turnover among heart failure specialists who act as Barostim champions within our active accounts. The need for heart failure specialists is growing faster than the supply because patient volumes keep rising and fewer doctors are going into the specialty. That situation was a major topic at the Heart Failure Society of America meeting last month. At HFSA, attendees pointed out that more than 50% of advanced heart failure fellowship slots went unfilled in 2026. That gap is leaving a lot of roles unfilled and driving heart failure physicians in practice to switch jobs more often. If a doctor who is a Barostim advocate at a busy account takes a job somewhere else, the Barostim program may lose momentum or halt altogether. Our field teams work to limit that kind of setback through two approaches. The first is building programs that last and hold up, weaving Barostim therapy into the wider heart failure care pathway; that way, the departure of one physician is less likely to bring a program down. Second, we support doctors when they transition into a new practice by offering introductions, help with networking, and other resources so a fresh Barostim program can be launched more quickly and smoothly in the new setting. Sadly, Barostim tends not to be an immediate focus for these physicians once they start their new positions, because they are frequently brought in to stabilize or grow highly lucrative end-stage heart failure offerings like left ventricular assist devices and heart transplantation; as a result, it usually requires three to four quarters before a new Barostim program becomes operational. The third challenge involves field execution, which depends heavily on the stability and experience of our salesforce. Our efforts to transform the sales organization have led to turnover that is above normal, and that has hurt our results, so we are acting to correct this. To begin, Paul Verrastro has been named interim head of sales. Paul has a strong track record as a commercial leader and is held in high regard by the field team. Putting this trusted CVRx veteran into the position has already had a major stabilizing effect on our people.

Kevin Hykes

executive
#3

Second, we've established new positions aimed at improving the span of control and available bandwidth for our frontline sales leaders, and we've made it a priority to fill those positions internally—elevating a seasoned sales leader to become our first area Vice President, and moving experienced territory managers into area sales director roles. Third, we've bolstered onboarding and training for new hires and put in place a more uniform approach to sales coaching throughout our sales director team; these measures will require time before they show up fully in our results, but we're already witnessing a favorable effect on stability and engagement across the team. Although it's still early, we're glad to report that turnover during Q3 fell to its lowest point in over two years, and average tenure for territory managers stands at a record high. That said, we continue to be cautious regarding the turnover outlook. Although these results amount to meaningful progress, it remains early, and over the long run we anticipate ongoing turnover at normal market rates. That leads me to the most important point regarding execution. Significant performance disparities persist across our nine U.S. regions. As we mentioned on our second quarter call, five regions are growing procedures by an average of more than 20%, even amid the reimbursement and physician champion headwinds described above. In the remaining four regions—where tenure is lowest at both the territory manager and leadership levels—speeding up our growth has proven difficult. Those regions have felt the headwinds discussed earlier more acutely, since their teams have less experience navigating such challenges. Those four regions are our priority. We're stabilizing the teams, backing our newer leaders, and equipping their organizations to run our playbook consistently. Our approach is identical in every region: execute our program selling strategy by building networks of aligned physicians who understand where Barostim fits within the heart failure continuum, who can spot patients likely to benefit, and who make Barostim an integral component of their disease management approach. A recent comprehensive analysis of the program selling strategy following the first 18 months of implementation found that the key differentiator among our most productive programs is the depth and breadth of their referral network. Per our analysis, they have four to five times as many referring and prescribing cardiologists as less productive non-program accounts, and consequently generate referrals and implants at a significantly higher rate. Our program development work at the account level is backed by our local, regional, and national medical education and awareness efforts. Our top five performing regions are leveraging these resources aggressively, which we believe is a key element of their success; these data suggest to us that we have the right strategy. The playbook clearly works when the right conditions are in place. Our focus is on creating these conditions for success in every region by ensuring there's a stabilized team, an optimized onboarding curriculum, and a common coaching approach. Our objective is straightforward: showing steady double-digit expansion throughout each of the nine regions. I'd like to wrap up on the clinical side, where developments remain highly positive. We maintained a substantial footprint at HFSA in October—our biggest conference this year—featuring nine podium and poster presentations, among them the late-breaking REBALANCE presentation. REBALANCE represents the biggest real-world Barostim cohort reported so far, enrolling 435 patients at 45 U.S. centers. Within the 238-patient subset matching the present U.S. commercial indication, findings showed lasting gains in New York Heart Association functional class throughout the 24-month follow-up period, plus a clinically meaningful and statistically significant rise in average left ventricular ejection fraction amounting to 4.8 percentage points at 12 months and 8 percentage points at 24 months. Real-world evidence of this kind serves as a valuable complement to randomized clinical trial data and assists clinicians and payers in grasping the outcomes they may anticipate from Barostim therapy in routine clinical practice. We expect that a substantial portion of the data from the HFSA presentations and posters will appear in scientific literature soon. BENEFIT-HF likewise drew considerable attention at the meeting and is generating notable visibility, credibility, and engagement among physicians. Demand for center activation remains strong, and we are witnessing an encouraging initial flow of enrollments as clinical teams incorporate the trial into their research offerings. A last clinical update concerns the new FDA real-world evidence pathway for expanding existing indications. We are engaged in talks with the FDA regarding a possible real-world evidence-based PMA supplement that would use this new pathway. We find these discussions encouragingly collaborative and hope to reach agreement with the FDA on a protocol in 2027. Should we succeed, we will proceed to run the analysis on our real-world dataset to examine a case for label expansion; we look forward to updating you on our progress as talks with the FDA carry on; to conclude, we are addressing the three headwinds already discussed and actively responding to each one. Our emphasis is on enhancing execution in our less tenured regions and capitalizing on the considerable strides we are making in evidence and awareness; we are gratified by the growing consistency of reimbursement for traditional Medicare patients and will keep advocating for Medicare Advantage patient access via the prior authorization process. We will additionally use our two written Medicare Advantage coverage policies to prompt more payers to follow that lead. We are highly pleased with the pace and impact of the clinical evidence we are assembling and with the strongly favorable response within the heart failure community to the BENEFIT-HF trial. Before handing the call to Jared for our financial results review, I want to introduce John Landry, our incoming Chief Financial Officer, who joined us in October. John has over 20 years of financial leadership experience in the medical device industry, and we're delighted that John has joined us. I also want to thank Jared, who has been an important part of this company for more than a decade, for his significant contributions to the company and for his continued engagement and support through this transition. John, welcome — and I'll turn it over to you for a few introductory remarks. Thank you.

John Landry

executive
#4

Thank you, Kevin. It’s exciting to be part of the CVRx team, and I’m eager to connect with many of you in the near future; during these first few weeks, my confidence in the CVRx opportunity has only grown stronger. I believe our team is passionate and patient-focused, and that we have excellent technology with best-in-class gross margins as well as an expanding body of clinical evidence. By achieving consistent revenue growth within this large multi-billion dollar heart failure market, I believe we can create substantial value over time; to close, I want to thank Jared for his support throughout this transition, and I’ll now hand the call to him so he can review our financial results.

Jared Oasheim

executive
#5

Thanks, John, and welcome. Unless stated otherwise, our year-over-year comparisons cover the three months ended September 30, 2026 versus the three months ended September 30, 2025. Total revenue came in at $13.8 million, down $0.9 million, or 6.1%. U.S. revenue was $13 million, a decline of $0.5 million, or 4%. U.S. revenue units were 412 versus 420. Those declines were mainly the result of the headwinds Kevin discussed earlier. Third quarter revenue also included higher-than-usual implants by centers that already had units available to implant, and that was more than offset by a larger annual purchase that landed in the third quarter, one we would otherwise have expected in the fourth quarter, so it is reflected in our fourth quarter guidance. We expect quarter-to-quarter variations to continue given these timing dynamics. We finished the quarter with 262 active implanting centers in the U.S., compared with 258 as of June 30, 2026, and 250 as of September 30, 2025. The center count reflects new centers being added while some lower-activity centers went inactive, which is consistent with our focus on deeper adoption within active centers. As of September 30, 2026, U.S. sales territories numbered 56, versus 50 as of September 30, 2025. Europe revenue was $0.9 million, down $0.3 million, or 27%. Total revenue units in Europe fell to 38 from 50 in the prior year period. Sales territories in Europe stayed consistent at five. Gross profit was $12 million, a decrease of $0.8 million, or 6%. Gross margin was 87%, consistent with 87% a year ago. R&D expenses declined $0.5 million, or 16%, to $2.7 million; that change was driven by a $0.4 million decrease in headcount expenses and a $0.2 million decrease in consulting expenses, partially offset by a $0.1 million increase in clinical trial expenses. SG&A expenses rose $0.5 million, or 2%, to $22.4 million; that change was primarily driven by a $0.7 million increase in legal expenses, a $0.4 million increase in travel expenses, and a $0.4 million increase in consulting and contract labor expenses, partially offset by a $0.8 million decrease in advertising expenses and a $0.1 million decrease in insurance expenses; in total, operating expenses were $25.1 million for the quarter and approximately $77 million year-to-date. Interest expense rose $0.1 million to $1.6 million; that increase was driven by higher interest expense resulting from increased borrowings under the term loan agreement with Innovatus Capital Partners. Other income net declined to $0.4 million from $0.9 million. That balance consisted of interest income on our interest-bearing accounts. Net loss was $14.2 million, or $0.52 per share, compared with a net loss of $12.9 million, or $0.49 per share. Net loss per share was based on 27.2 million and 26.2 million weighted average shares outstanding, respectively. By September 30, 2026, our cash and cash equivalents stood at $58.7 million, versus $64.6 million on June 30, 2026, and $85.1 million on September 30, 2025. Cash used in operating and investing activities on a net basis came to $11 million, against $10 million for the three months that ended September 30, 2025. We also brought in roughly $6 million during the quarter through our at-the-market facility. Thanks to the OpEx cuts we've implemented, we think we have a cash runway of at least 18 months. That runway excludes any further proceeds from the ATM. I'll now move to guidance. For the full year 2026, total revenue is now expected to land between $56 million and $57 million, versus the $58 million-$60 million range we gave previously. For Q4 2026, we expect total revenue of between $11.7 million and $12.7 million; this shift reflects the ongoing effect of reimbursement delays involving our largest Medicare Advantage payer, the impact of physician champion turnover, and a recovery in our less tenured regions that has been slower than anticipated; we still expect gross margin for the full year of between 86% and 87%. Given this revenue outlook, we've put in place a comprehensive set of measures aimed at lowering our baseline cost structure. Among them were cuts to non-commercial functions, even as we keep investing in our sales and reimbursement teams. We're being disciplined when it comes to filling open positions, and we've scaled back marketing and R&D projects that we don't expect to affect revenue. We still expect full-year operating expenses of between $99 million and $101 million, which reflects these actions, including one-time severance charges recognized in the second half of 2026. Before I finish, I want to say that helping build CVRx with this team since 2015 and bringing Barostim to more patients has been a privilege. I'm confident John will be a wonderful partner to Kevin, to the team, and to all of you, and I thank you for the support you've given over the years. With that, I'll hand the call back to Kevin now for his closing remarks.

Kevin Hykes

executive
#6

Thank you, Jared. Before we wrap up, I'd like to give a summary of where things stand. Both the third quarter and our revised outlook show genuine difficulties, especially the reimbursement holdups involving our biggest Medicare Advantage payer. We're tackling every one of these headwinds head-on, and we've trimmed some operating expenses while still funding our growth drivers. Getting our growth to speed up is going to take more time than we'd prefer, and we anticipate the payoff from these steps will come together gradually, yet our confidence in the result and in what this therapy is worth has not wavered. The need itself is unchanged. Today, 6.7 million Americans are living with heart failure. Roughly 339,000 of those patients carry an indication for Barostim, and about 76,000 newly diagnosed patients enter our indication each year. Together that represents a $10.5 billion market opportunity, and our penetration is under 2%. Given an 87% gross margin, our attention is firmly on returning this business to a growth path; we have a therapy that works, a sizable market with considerable room to expand, and a team working daily to change the way heart failure is treated. That is why I stay enthusiastic about what we can build together and about the value we can create for patients, physicians, payers, and our shareholders. At this point, I'd like to open the line for questions. Operator?

Max Smock

analyst
#7

Hey everyone, this is Max here, filling in for Brandon. Am I coming through clearly?

Kevin Hykes

executive
#8

Loud and clear.

Max Smock

analyst
#9

Yeah. Hey, thanks, guys. There's a lot going on here. Could you just double-click on what's baked into the Q4 2026 guidance, and how should we think about some of these headwinds? Again, I know it's early, but how should we think about some of these headwinds as we start to fine-tune our models for 2027?

Kevin Hykes

executive
#10

Yeah. I'll take the headwinds first, Max. Thank you. Obviously, as we laid them out, the real impactor here has been the continued degradation of UnitedHealth, our largest and formerly most predictable and consistent payer. And that has just continued to decline now to a 12% level versus 83.5% a year ago. That's been a big headwind for us, definitely this quarter. The second one involves champion turnover, something we've been monitoring for a while, trying to figure out whether it was regional or episodic, maybe just a summer phenomenon. And we've now concluded—particularly after last month's Heart Failure Society meeting—that this is, unfortunately, the new reality in heart failure. The U.S. has only around 1,400 heart failure specialists, far fewer than you'd normally expect given how large the disease state is. The problem is that very few new physicians are coming into the field. Last month, speakers on the podium said at several moments that their specialty is struggling and possibly facing a crisis, since the field isn't drawing new physicians. In fact, just 60% of fellowships were filled last year. The figure I heard from the podium last month for this year was that 43% of available heart failure specialist fellowship positions in the U.S. got filled, meaning 57% went empty. As you can imagine, this is driving a lot of job hopping and a lot of unfilled roles, which creates difficulties for our programs. The third factor—fortunately, something we can influence more directly—relates to how our field teams are performing. We're glad to report that in areas where people have been with us longer and where seasoned leaders are executing our playbook, average growth is exceeding 20%. That covers the five regions with the most tenure among our nine. In four of the nine regions, the leadership team lacks that same tenure or experience, and those regions are finding it hard to match that growth. This falls within our control, and we're putting substantial effort into lifting those four regions to the same standard of execution. I might hand it to Jared to explain how that factors into guidance.

Jared Oasheim

executive
#11

Yes, Max, what we said before was that for Q4 we'd be looking at somewhere in the range of $11.7 million to $12.7 million. For the full year, that works out to $56 million to $57 million. To repeat what Kevin mentioned, the effect coming from the biggest Medicare Advantage payer is putting pressure on those figures. Given what we can see right now, those are the results we anticipate for the fourth quarter.

Max Smock

analyst
#12

That's useful. Kevin, one more thing for you. My understanding is that last quarter — and tell me if I've got this wrong — there was one big Medicare Advantage payer with a coverage policy, and now there are two. Can you folks do anything on your end proactively so a third one doesn't follow?

Kevin Hykes

executive
#13

Apologies, there might be a bit of confusion on that. We did add a second written coverage policy in August, coming from a top 10 provider; that policy, together with Humana, has actually seen markedly better approval rates. Humana is getting close to 80% or 90%. Naturally, since they have a written coverage policy, they're approving virtually every prior authorization almost right away. Aside from that, UnitedHealthcare, which is our biggest payer, has no written coverage policy. Because of that, and because of how dramatically they've changed behavior since Q1, they turn down every single prior authorization submitted, and in a great many cases they turn down the first, second, and third appeal. Our strategy is actually to get as many payers as we possibly can to write policies, and obviously that includes UnitedHealth. How you make that happen is by taking every denial and appealing it, then pushing those appeals all the way to the administrative law judge following the third denial, if that's what it takes, and hopefully winning at the ALJ level. Once you rack up enough wins there — and the payer foots the bill for those — they eventually flip and write a policy, just like what happened with Humana. Sorry if I wasn't clear on that earlier, but we're doing this with every prior auth submitted. The problem for us is that we can only see less than half, maybe roughly a third, of the prior authorizations for Barostim. That third of prior authorizations goes through our internal system, our C-PAS group, so we know precisely what happens to those. What's invisible to us is what's going on with approximately two-thirds of the remaining prior auths out in the market. We know as a fact, as holds true across the industry, that only 20% of denials ever get appealed by a clinician group or a hospital system. If those UnitedHealth prior auths are getting denied, chances are they aren't being appealed, and those are patients who were on our therapy and now aren't. I hope that answers your question.

Nick Mattiacci

analyst
#14

Hey, guys. Nick Mattiacci here, speaking on behalf of Chase. Appreciate you taking our questions. Regarding the planned cost savings, could you help us put a number on the annualized savings, and how should we think about the operating expense run rate as we head into 2027? And then on that same subject, you mentioned that you're still investing in sales and reimbursement while cutting spend in other areas. How should we think about the net effect of those moves?

Jared Oasheim

executive
#15

Yeah, I can handle that one. Thanks for the questions; we're not going to go too deep on 2027 operating expense guidance right now, but here's what we can say: this action involved a moderate level of headcount reductions, and a few additional project spend items were paused for the time being, and for the most part those weren't tied to our sales or marketing organizations. We won't get into details on the total value of the cost savings, but our total OpEx figure came in roughly the same for the year as what we had previously guided, since we also took on some extra severance costs in Q4 that weren't part of the original plan. Those two roughly offset each other. But heading into 2027, we'll have a lower cost base that we can build from going forward.

Nick Mattiacci

analyst
#16

Understood. So, going back to that big Medicare Advantage payer that's been giving you trouble: could you say more about what you believe has to occur for those rates to get better, and do you see a realistic route to sorting these problems out with that payer?

Kevin Hykes

executive
#17

Yes. As I said, the way that gets resolved is ultimately for this payer to put a policy in writing. Like I mentioned with Humana, every ALJ loss runs these payers about $10,000. If they eventually conclude that once they begin losing over 50% of the ALJ cases, and once we can drive enough of those denials through the ALJ process, then in the end it serves their best interest to write a policy. That's precisely what took place with Humana. So that's the strategy we're following with United, our biggest payer. What it takes is time, and each of these ALJ — the ALJ process by itself runs more than 100 days after the third denial. That comes on top of the first three cycles; so it takes time to build up those cases, to push them through the ALJ, and to begin winning. But that is in fact what happened with Humana. We were winning 57% of the time when they finally wrote the policy; so that's the approach and the playbook. It isn't a Barostim playbook. That's sort of the commonly accepted industry approach to generating leverage and support for eventual written coverage policies. Was there a second part to the question? Sorry if I missed that.

Nick Mattiacci

analyst
#18

Oh, no. You've addressed all of it. I appreciate that. Then, regarding the greater-than-normal volume of implants drawn from hospital inventory, could you somehow quantify what that dynamic did and, I mean, perhaps give us a clearer picture of the underlying growth in implant volume?

Jared Oasheim

executive
#19

Yeah, glad to handle that one. I believe the point in flagging it was that, you know, we had a bigger purchase happen in last year's fourth quarter, sort of the usual pattern, year-end customers, you know, attempting to hit their rebate levels. We actually saw that comparable customer, that very same customer, make such a purchase in this year's Q3. And the reason we flagged it was more to help clarify the Q4 guidance, as we're looking at that. But we won't go into further specifics about the quantities that those kinds of deals involved.

Nick Mattiacci

analyst
#20

Got it. Appreciate you fielding the questions.

Kevin Hykes

executive
#21

Thanks, operator, and thank you all for being with us today; we're grateful for your ongoing support and we look forward to bringing you up to date on how we're doing next quarter. Thanks.

Operator

operator
#22

That brings us to the end of today's teleconference. At this point, you're welcome to disconnect your lines. Thank you for joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete CVRx, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to CVRx, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in CVRx, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.